Journal
DRUG DISCOVERY TODAY
Volume 27, Issue 1, Pages 347-353Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.09.014
Keywords
Health Technology Assessment; Early scienti fic advice; Drug development; Reimbursement; Regulator; Parallel scienti fic advice
Categories
Ask authors/readers for more resources
There is a growing trend for pharmaceutical companies to seek scientific advice on drug development from a Health Technology Assessment (HTA) perspective, to improve the efficiency of their studies and support positive HTA recommendations. This study evaluates pharmaceutical companies' strategies and practices for seeking HTA-related scientific advice based on information collected directly from companies.
There is a growing trend for pharmaceutical companies to seek scientific advice on drug development from a Health Technology Assessment (HTA) perspective, to improve the efficiency of their studies, enable better trial design, and support the goals of positive HTA recommendation for reimbursement. This study uses information collected directly from companies on individual products to assess their strategies and practices for seeking HTA-related scientific advice in terms of which stakeholders to engage and for what purpose, when to seek scientific advice, and whether to implement that advice within global clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available